Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ROCKWELL MEDICAL, INC. (RMTI)
|
Add to portfolio |
|
|
|
| Price: |
$0.45
| | Metrics |
| OS: |
28.5
|
M
| |
|
|
| Market cap: |
$12.7
|
M
| |
|
|
|
Net cash:
|
$4.76
|
M
| |
$0.17
|
per share
|
|
EV:
|
$7.95
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 61.9 | 62.2 | 61.3 | 63.4 | 57.3 | 53.3 | 55.4 | 54.2 |
| Revenue growth | -0.4% | 1.5% | -3.3% | 10.6% | 7.5% | -3.7% | 2.1% | 3.5% |
| Cost of goods sold | 64.4 | 59.5 | 58.5 | 65.0 | 53.6 | 46.5 | 46.4 | 45.6 |
| Gross profit | -2.4 | 2.7 | 2.8 | -1.6 | 3.7 | 6.8 | 8.9 | 8.5 |
| Gross margin | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.1% | 15.8% |
| Selling, general and administrative | | | | | 23.3 | 21.1 | 19.1 | 18.3 |
| Sales and marketing | 5.7 | 7.9 | 9.1 | 1.0 | | | | |
| Research and development | 6.8 | 7.1 | 6.9 | 5.6 | 6.3 | 5.8 | 5.0 | 7.8 |
| General and administrative | 15.3 | 16.2 | 21.0 | 22.1 | | | | |
| EBIT | -30.3 | -28.4 | -34.5 | -31.3 | -25.9 | -20.2 | -15.1 | -17.6 |
| EBIT margin | -49.0% | -45.7% | -56.3% | -49.4% | -45.2% | -37.9% | -27.3% | -32.4% |
| Pre-tax income | -32.7 | -30.9 | -34.1 | -32.1 | -25.9 | -19.4 | -14.4 | -21.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% |
| Net income | -32.7 | -30.9 | -34.1 | -32.1 | -25.9 | -19.8 | -14.4 | -21.3 |
| Net margin | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% |
| |
| Diluted EPS | ($0.35) | ($0.41) | ($0.56) | ($0.61) | ($0.51) | ($0.39) | ($0.29) | ($0.52) |
| Shares outstanding (diluted) | 93.8 | 75.6 | 60.9 | 52.8 | 51.1 | 50.7 | 50.1 | 41.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|